Author of

• 18749

  +

  P3.07 - Poster Session with Presenters Present (ID 493)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Regional Aspects/Health Policy/Public Health
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 18757

    +

    P3.07-008 - METASTATIC NSCLC: Treatment Reality from 182 Cases of Lung Adenocarcinoma in a Brazilian Public Cancer Health Service (ID 5950)

    14:30 - 14:30  |  Author(s): B.T. Da Silva
    • Abstract

    Background:
    Background: In Brazil, lung cancer is a public health problem as in the world. The national Incidence in 2016 is estimated in 28.220 new cases[1]. In Rio Grande do Sul, an etimated number of new cases is 4.240[1]. Is well estabilished molecular testing for EGFR, ALK mutations are mandatory to treat metastatic adenocarcinomas to indicate target therapy, or not. Prevalence of EGFR mutations in adenocarcinomas, for example, are estimeted from 25,5% to 30,4%[2,3]. Although many guidelines advocates to use a TKI as first line therapy, in Brazil is difficult becouse nor the drugs, nor the assays are available to public health service, except by legal measures[4], or support from pharmaceutical industry
    
    Methods:
    Methods: We made a cross-sectional study from january 2013 to may 2016, collecting data from medical records in our institution, to evaluate our population and how we are handling advanced and metastatic adenocarcinomas in NSCLC patients.
    
    Results:
    Results:We found 182 patients with NSCLC (adenocarcinoma), from those 72 was in stage IIIB-IV or with relapsed disease. In 37/72 (51,38%) cases some molecular testing was done (EGFR, ALK); EGFR 26 (36,1%) WT: 9/26 (34,6%), mut: 9/26 (34.6%)(in confirmation), UK (data in confirmation): 8/26 (30,7%); ALK: 10 (13,8%), w-o transloc.: 6/10 (60%); wtransloc: 1/10 (10%); UK (data in confirmation)3/10 (30%). From 72 patients, nine (12,5%) was included in clinical trials; 6/72 (8.33%) recived TKI out of a trial. From these just 2/6 received TKI as first line, and 4/6 as a second line and beyond.
    
    Conclusion:
    Conclusions: It will be done after our sample, and assay tests results review.